JPRN-UMIN000022931
Completed
Phase 2
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer - PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer
Rakuwakai Otowa Hospital Breast oncology department0 sites24 target enrollmentJuly 1, 2016
ConditionsBreast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Breast cancer
- Sponsor
- Rakuwakai Otowa Hospital Breast oncology department
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of hypersensitivity reaction 2\) Active double cander 3\) Other severe complications, such as infections, diarrhea, uncontrolled angina, myocardial infarction within 6 months, heart failure. 4\) Case of contraindication of this drug 5\) Patients with peripheral nerve symptoms 6\) Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 7\) Judged ineligible based on physicians' decision
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancerbreast cancerJPRN-UMIN000006020Tokai University School of Medicine50
Recruiting
Phase 2
Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastasesJPRN-UMIN000010685Saitama Medical Center,Saitama Medical University40
Recruiting
Phase 2
A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.breast cancerJPRN-UMIN000017382Tokyo Women's Medical University,Department of endocrine surgery36
Completed
Phase 2
Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancerbreast cancerJPRN-UMIN000011048Kitasato University Kitasato Institute Hospital20
Completed
Phase 2
A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancerBreast CancerJPRN-UMIN000009733Hiroshima city hospital40